NCT06886360View on ClinicalTrials.gov

Study with Norucholic Acid Tablets in Patients with Primary Sclerosing Cholangitis (PSC)

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

March 31, 2025

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2027

Conditions
Primary Sclerosing Cholangitis
Interventions
DRUG

norucholic acid

500 mg norucholic acid film-coated tablets; 3 tablets/day

Sponsors
All Listed Sponsors
lead

Dr. Falk Pharma GmbH

INDUSTRY

NCT06886360 - Study with Norucholic Acid Tablets in Patients with Primary Sclerosing Cholangitis (PSC) | Biotech Hunter | Biotech Hunter